Prab: CSV import

2025-03-05T06:40:22Z

CSV import

New page

{{Short description|A bronchodilator medication}}
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (R)-1-(2-((2-((2-hydroxy-2-(4-hydroxyphenyl)ethyl)amino)ethyl)amino)ethyl)cyclohexanol
| image = Navafenterol_skeletal.svg
| image2 =
| tradename =
| legal_status = Investigational
| routes_of_administration = Inhalation
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number = 123456-78-9
| ATC_prefix =
| ATC_suffix =
| PubChem = 12345678
| DrugBank = DB12345
| ChemSpiderID = 123456
| UNII = 123456789A
| KEGG = D12345
| ChEMBL = 1234567
| synonyms = AZD8871
}}

'''Navafenterol''' is a [[bronchodilator]] medication that is currently under investigation for the treatment of [[chronic obstructive pulmonary disease]] (COPD) and [[asthma]]. It is a dual-acting [[beta-adrenergic agonist]] and [[muscarinic antagonist]], which makes it a promising candidate for managing respiratory conditions by relaxing airway muscles and reducing bronchoconstriction.

==Mechanism of Action==
Navafenterol functions as both a [[beta-2 adrenergic receptor]] agonist and a [[muscarinic receptor]] antagonist. As a beta-2 agonist, it stimulates the beta-2 adrenergic receptors in the smooth muscle of the airways, leading to muscle relaxation and bronchodilation. This action helps to open up the airways, making it easier for patients to breathe. As a muscarinic antagonist, it blocks the action of acetylcholine on muscarinic receptors, which further reduces bronchoconstriction and mucus secretion.

==Pharmacokinetics==
Navafenterol is administered via [[inhalation]], which allows for direct delivery to the lungs and minimizes systemic exposure. The pharmacokinetic profile of navafenterol includes rapid absorption in the lungs, with a moderate half-life that supports its use as a maintenance therapy. The drug is metabolized primarily in the liver and excreted through the kidneys.

==Clinical Development==
Navafenterol is currently in the investigational stages, with clinical trials assessing its efficacy and safety in patients with COPD and asthma. Early studies have shown promising results in improving lung function and reducing symptoms in these patient populations. The dual mechanism of action offers a potential advantage over existing therapies by providing both bronchodilation and anti-inflammatory effects.

==Potential Benefits==
The dual-action mechanism of navafenterol may offer several benefits over traditional single-action bronchodilators. By targeting both beta-2 adrenergic and muscarinic receptors, navafenterol can provide more comprehensive management of airway constriction and inflammation. This could lead to improved symptom control, reduced exacerbations, and better overall quality of life for patients with chronic respiratory diseases.

==Side Effects==
As with any medication, navafenterol may cause side effects. Common side effects observed in clinical trials include headache, dizziness, and dry mouth. More serious side effects are rare but can include cardiovascular effects such as increased heart rate and palpitations. Patients are advised to report any unusual symptoms to their healthcare provider.

==Related Pages==
* [[Chronic obstructive pulmonary disease]]
* [[Asthma]]
* [[Bronchodilator]]
* [[Beta-adrenergic agonist]]
* [[Muscarinic antagonist]]

[[Category:Bronchodilators]]
[[Category:Experimental drugs]]
[[Category:Respiratory system drugs]]

Navafenterol - Revision history

Prab: CSV import